The latest notes bring Bay City's total investment in the company to , SynGen's President and Chief Executive Officer. "The latest financing will allow us to make our first sales of the SynGenX-1000 System to cord blood banks, and to continue to commercialize the SynGenX-Lab and CellWashPRO devices for stem cell processing customers.
http://www.biospace.com/news_story.aspx?StoryID=348971&full=1
http://www.biospace.com/news_story.aspx?StoryID=348971&full=1
No comments:
Post a Comment